Cancers · 2019 · 32 citations · 54 references
MedicineMolecular GeneticsOncologyCancer GeneticsMetastasisMolecular OncologyCancer GenomicsComparative Genomic HybridizationMolecular Tumor ProfilingNext-generation Sequencing In OncologyActionable Genomic AlterationsArray Comparative Genomic HybridizationCyclin-dependent Kinase InhibitorsMutationPhosphatidylinositol 3-Kinase-akt PathwayPoly Adp-ribose Polymerase InhibitorsTargeted Next-generation SequencingTumor Mutational Burden
Improving the systemic treatment of brain metastases (BM) in primary breast cancer (PBC) is impaired by the lack of genomic characterization of BM. To estimate the concordance of DNA copy-number-alterations (CNAs), mutations, and actionable genetic alterations (AGAs) between paired samples, we performed whole-genome array-comparative-genomic-hybridization, and targeted-next-generation-sequencing on 14 clinical PBC-BM pairs. We found more CNAs, more mutations, and higher tumor mutational burden, and more AGAs in BM than in PBC; 92% of the pairs harbored at least one AGA in the BM not observed in the paired PBC. This concerned various therapeutic classes, including tyrosine-kinase-receptor-inhibitors, phosphatidylinositol 3-kinase/AKT/ mammalian Target of Rapamycin (PI3K/AKT/MTOR)-inhibitors, poly ADP ribose polymerase (PARP)-inhibitors, or cyclin-dependent kinase (CDK)-inhibitors. With regards to the PARP-inhibitors, the homologous recombination defect score was positive in 79% of BM, compared to 43% of PBC, discordant in 7 out of 14 pairs, and positive in the BM in 5 out of 14 cases. CDK-inhibitors were associated with the largest percentage of discordant AGA appearing in the BM. When considering the AGA with the highest clinical-evidence level, for each sample, 50% of the pairs harbored an AGA in the BM not detected or not retained from the analysis of the paired PBC. Thus, the profiling of BM provided a more reliable opportunity, than that of PBC, for diagnostic decision-making based on genomic analysis. Patients with BM deserve an investigation of several targeted therapies.
54
Comprehensive molecular portraits of human breast tumours
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers, Caitlin Connelly, David Fabrizio et al. · Genome Medicine · 2017 · 3.7K citations · Full text
Medicine, Cancer Biology, Oncology +17
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17